0001640455-20-000089.txt : 20200702
0001640455-20-000089.hdr.sgml : 20200702
20200702193540
ACCESSION NUMBER: 0001640455-20-000089
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200626
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KARSEN PERRY A
CENTRAL INDEX KEY: 0001260573
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 201011638
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4/A
1
wf-form4a_159373292481119.xml
FORM 4/A
X0306
4/A
2020-06-26
2020-06-29
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001260573
KARSEN PERRY A
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
0
0
0
Stock Option (Right to Buy)
7.58
2020-06-26
4
A
0
15700
0
A
2030-06-26
Common Stock
15700.0
15700
D
The original Form 4 filed on June 29, 2020 erroneously reported 13,550 shares of common stock subject to the stock option. This amendment is being filed to disclose the correct number of shares subject to the reported stock option.
The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.
/s/ Kim C. Drapkin, Attorney-in-Fact
2020-07-02